Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses new strategies for clinical trial design in multiple myeloma (MM). Prof. McCarthy highlights measurable residual disease and covers the different techniques that can be used to determine this. This video was recorded at the 1st European Myeloma Network Meeting, in Turin, Italy.
Predicting long-term outcomes in myeloma: MRD
